- Home
- CELC
CELC
Celcuity Inc.
as 11-06-2025 3:52pm EST
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Upcoming Earnings Alert:
Get ready for potential market movements as Celcuity Inc. CELC prepares to release earnings report on 12 Nov 2025.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 3.1B | IPO Year: | 2017 |
| Target Price: | $69.40 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.58 - $83.00 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Celcuity Inc. (CELC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | CELC | 10% Owner | Sep 8 '25 | Buy | $57.12 | 170,100 | $9,571,318.56 | 703,920 |
Latest Celcuity Inc. News
CELC Breaking Stock News: Dive into CELC Ticker-Specific Updates for Smart Investing
Simply Wall St.
17 days ago
Celcuity (CELC) Is Up 52.8% After Promising Phase 3 Breast Cancer Trial Data and FDA Submission Progress. Has The Bull Case Changed?
Simply Wall St.
17 days ago
Celcuity (CELC): Examining Valuation After a 437% Year-to-Date Share Price Surge
Investor's Business Daily
17 days ago
Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results
MT Newswires
17 days ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
17 days ago
Sector Update: Health Care
MT Newswires
17 days ago
Celcuity Shares Jump After Phase 3 Trial Shows Gedatolisib Boosts Progression-Free Survival in Breast Cancer
MT Newswires
18 days ago
Top Midday Gainers
MT Newswires
18 days ago
Wall Street Set to Open Higher Monday as Investors Look Ahead to a Week of Earnings Reports
Compare CELC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CELC Celcuity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.